AtriCure, Inc. (NASDAQ:ATRC) Stock Holdings Raised by Hood River Capital Management LLC

Hood River Capital Management LLC increased its stake in AtriCure, Inc. (NASDAQ:ATRC) by 3.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,923,731 shares of the medical device company’s stock after purchasing an additional 93,131 shares during the quarter. AtriCure comprises about 1.3% of Hood River Capital Management LLC’s portfolio, making the stock its 23rd biggest holding. Hood River Capital Management LLC owned 0.06% of AtriCure worth $89,349,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in ATRC. Geode Capital Management LLC grew its position in AtriCure by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company’s stock worth $32,326,000 after purchasing an additional 32,676 shares during the last quarter. Silver Oak Securities Incorporated acquired a new position in shares of AtriCure in the fourth quarter valued at approximately $220,000. JPMorgan Chase & Co. boosted its holdings in AtriCure by 43.1% during the fourth quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company’s stock worth $11,160,000 after purchasing an additional 110,039 shares during the last quarter. Calamos Advisors LLC raised its position in AtriCure by 27.9% during the fourth quarter. Calamos Advisors LLC now owns 110,671 shares of the medical device company’s stock worth $3,382,000 after acquiring an additional 24,147 shares in the last quarter. Finally, M&T Bank Corp bought a new position in shares of AtriCure during the fourth quarter worth approximately $208,000. 99.11% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now directly owns 17,828 shares in the company, valued at $679,603.36. This trade represents a 25.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.20% of the stock is owned by corporate insiders.

AtriCure Price Performance

ATRC stock opened at $31.97 on Wednesday. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -33.65 and a beta of 1.65. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11. The firm has a 50 day moving average of $34.73 and a 200-day moving average of $34.48.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ATRC shares. Oppenheimer increased their price target on AtriCure from $36.00 to $45.00 and gave the company an “outperform” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. reduced their target price on AtriCure from $51.00 to $46.00 and set an “overweight” rating for the company in a report on Thursday, March 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $51.00 price objective on shares of AtriCure in a report on Thursday, March 27th. JMP Securities restated a “market outperform” rating and issued a $60.00 price objective on shares of AtriCure in a research report on Monday, February 10th. Finally, BTIG Research reaffirmed a “buy” rating on shares of AtriCure in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $49.44.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.